Takeda's Ninlaro combo fails to hit main goal in newly diagnosed, transplant ineligible multiple myeloma

Takeda has unveiled new Phase 3 data for its oral proteasome inhibitor Ninlaro (ixazomib) in the treatment of newly diagnosed transplant ineligible multiple myeloma, revealing that the therapy, when combined with lenalidomide and dexamethasone, unfortunately did not meet its primary endpoint.

The combo was shown to improve median progression-free survival by 35.3 months compared to 21.8 months with lenalidomide and dexamethasone alone – an overall improvement of 13.5 months, but this was not to a degree that was considered statistically significant.

The combo’s safety profile was found to be in line with previous research.

“There is a need for treatment options in transplant ineligible patients. We remain committed to advancing the field of multiple myeloma and continue to drive innovation through ongoing research and development,” said Christopher Arendt, Head of Takeda’s Oncology Therapeutic Area Unit. “We are confident there will be numerous learnings from this trial and look forward to sharing these data with the community. We want to thank the patients and investigators for their participation in this important programme.”

The full results of the study will be revealed at an upcoming medical event, Takeda confirmed.

Matt Fellows